deltatrials
Enrolling By Invitation PHASE2 INTERVENTIONAL 1-arm NCT07209332

Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

An Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, Pharmacokinetics, and Efficacy of WVE-N531 in Patients With Duchenne Muscular Dystrophy Who Participated in Another Study of WVE-N531

Sponsor: Wave Life Sciences Ltd.

Conditions Duchenne Muscular Dystrophy
Interventions WVE-N531
Updated 2 times since 2025 Last updated: Mar 4, 2026 Started: Dec 28, 2025 Primary completion: Mar 31, 2029 Completion: Mar 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07209332, this PHASE2 trial focuses on Duchenne Muscular Dystrophy and remains ongoing. Sponsored by Wave Life Sciences Ltd., it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Nov 2025 – ~Mar 2026 · 4 months · monthly snapshotNot Yet Recruiting~Mar 2026 – present · 4 months · monthly snapshotEnrolling By Invitation

Change History

2 versions recorded

  1. Mar 2026 — Present [monthly]

    Enrolling By Invitation PHASE2

    Status: Not Yet Recruiting → Enrolling By Invitation

  2. Nov 2025 — Mar 2026 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Wave Life Sciences Ltd.
Data source: Wave Life Sciences Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations